CompletedPhase 2

Study to Assess the Efficacy and Safety of CLBS12 in Patients with Critical Limb Ischemia (CLI)

Japan33 participantsStarted 2017-11-01

Plain-language summary

A prospective, open label, controlled, randomized, double arm, multi-center study to assess the efficacy and safety of CLBS12 in patients with critical limb ischemia (CLI) due to arteriosclerosis obliterans (ASO) with a single arm sub-study to assess the safety and potential efficacy of CLBS12 in patients with CLI due to Buerger's Disease (BD).

Who can participate

Age range20 Years – 85 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * subject has CLI caused by ASO or BD Exclusion Criteria: * \< 20 years old

What they're measuring

Time to continuous CLI-free status

Timeframe: 1 year

Trial details

NCT IDNCT02501018

SponsorLisata Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2022-05-19

View on ClinicalTrials.gov More Critical Limb Ischemia trials